Journal of Surgical Oncology · 2005 · 41 citations · 19 references
MedicineMolecular BiologyUrologyGene ExpressionMolecular OncologyTumor ProgressionBenign Prostatic HyperplasiaBiomarkers In Genitourinary CancerCancer BiomarkersProstate CancerProstate PathologyProstatic PathologyBiomarkersImmunohistochemical BiomarkersMicroarray AnalysisNeoplastic ProgressionProstate Cancer PrognosisProstatic BiomarkersProtein Expression BiomarkersReverse Transcription Polymerase Chain Reaction (Rt-pcr)
BACKGROUND AND OBJECTIVES: Prostate carcinoma (CaP) is the frequently diagnosed cancer in man. Prostate specific antigen (PSA), which is now widely used as a diagnostic marker for CaP, lacks specificity and fails to predict possible CaP progression. So it is necessary to identify the new biomarkers for CaP. METHOD: We identified several genes that were differentially expressed between benign prostatic hyperplasia and CaP by microarray analysis. One gene that was overexpressed encoded a serine/threonine kinase PIM-1. Reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemical analysis were used to investigate PIM-1 mRNA and protein expression in malignant and benign prostate samples. RESULT: PIM-1 was overexpressed in CaP, and the overexpression of PIM-1 was related to the grade and neoplastic transformation of CaP. CONCLUSIONS: The data, together with the molecular functions of PIM-1 suggest that PIM-1 may have an important role in CaP progression and has potential to be a diagnostic and prognostic marker for CaP.
19
Delineation of prognostic biomarkers in prostate cancer
Saravana M. Dhanasekaran, Terrence R. Barrette, Debashis Ghosh et al. · Nature · 2001 · 1.7K citations · Full text
William J. Catàlona, Frederick R. Ahmann, M’Liss A. Hudson et al. · The Journal of Urology · 1994 · 1.4K citations
Expression profiling reveals hepsin overexpression in prostate cancer.
Jeffrey A. Magee, Toshiyuki Araki, Santosh Patil et al. · PubMed · 2001 · 393 citations